{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibr464pshyl4uvc27epjdamg4c7wq5xsgvbh2ohdlk2idjp4p6cmu",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mmqonwmya532"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia425qioztv4i257mziy4jyvaetwy77geyc5okknah4blm2nvf72m"
    },
    "mimeType": "image/jpeg",
    "size": 110576
  },
  "path": "/2026/05/25/eli-lilly-verv-102-gene-editing-cholesterol-phase-1-trial-data/?utm_campaign=rss",
  "publishedAt": "2026-05-25T12:45:00.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Pharma",
    "biotechnology",
    "Eli Lilly",
    "gene editing",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.",
  "title": "STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study",
  "updatedAt": "2026-05-25T14:09:43.000Z"
}